One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study

Yuji Oshima, Kenichi Kimoto, Noriko Yoshida, Kimihiko Fujisawa, Shozo Sonoda, Toshiaki Kubota, Toshinori Murata, Taiji Sakamoto, Shigeo Yoshida, Koh Hei Sonoda, Tatsuro Ishibashi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Purpose: To evaluate 1-year outcomes of intravitreal injections of aflibercept (IVA) in Japanese polypoidal choroidal vasculopathy (PCV) patients. Methods: In this prospective, open-label, single-arm multicenter clinical trial, treatment-naïve PCV patients received IVA (2.0 mg) every 2 months, after 3 initial monthly doses. The primary endpoint assessed was the proportion of patients maintaining baseline best-corrected visual acuity (BCVA) at 1 year. Results: Fifty eyes with PCV were included in the study. BCVA was maintained or improved in 97.6% of the patients. Mean logMAR BCVA at baseline was 0.33, and had improved to 0.12 logMAR 1 year after the initiation of aflibercept treatment (p < 0.001). Mean central foveal thickness decreased from 356 to 239 μm (p < 0.001). Complete regression of polypoidal lesions was seen in 72.5% after 1 year of treatment. Conclusions: One year of IVA resulted in stabilization of BCVA and anatomical improvement in Japanese PCV patients.

Original languageEnglish
Pages (from-to)163-171
Number of pages9
JournalOphthalmologica
Volume238
Issue number3
DOIs
Publication statusPublished - Sep 1 2017

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

Fingerprint Dive into the research topics of 'One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study'. Together they form a unique fingerprint.

  • Cite this

    Oshima, Y., Kimoto, K., Yoshida, N., Fujisawa, K., Sonoda, S., Kubota, T., Murata, T., Sakamoto, T., Yoshida, S., Sonoda, K. H., & Ishibashi, T. (2017). One-year outcomes following intravitreal aflibercept for polypoidal choroidal vasculopathy in Japanese patients: The APOLLO study. Ophthalmologica, 238(3), 163-171. https://doi.org/10.1159/000477448